| 21.05 11:20 | dpa-AFX: Sanofi, OpenAI To Build AI Software To Boost Drug Development |
| 21.05 08:01 | dpa-AFX: Sanofi, Formation Bio, OpenAI Announce AI Collaboration |
| 21.05 07:51 | dpa-AFX: *SANOFI, FORMATION BIO, OPENAI COLLABORATE ON AI DRUG DEVELOPMENT ACCELERATION |
| 21.05 07:30 | dpa-AFX: GNW-Adhoc: Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration |
| 20.05 20:15 | dpa-AFX: GNW-Adhoc: Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM |
| 14.05 02:41 | dpa-AFX: *SIEMENS AND SONY PARTNER TO BRING NX IMMERSIVE DESIGNER, INCLUDING SONY'S XR HEAD-MOUNTED DISPLAY |
| 13.05 12:37 | FDA prüft Antrag von Regeneron und Sanofi für Dupixent vorrangig |
| 13.05 12:33 | dpa-AFX: Fulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For Losmapimod |
| 13.05 12:23 | dpa-AFX: ANALYSE-FLASH: Deutsche Bank Research belässt Sanofi auf 'Sell' - Ziel 80 Euro |
| 13.05 12:23 | dpa-AFX: Deutsche Bank Research belässt Sanofi auf 'Sell' - Ziel 80 Euro |
| 13.05 12:15 | dpa-AFX: *FULCRUM THERAPEUTICS ENTERS LICENSE DEAL WITH SANOFI FOR DEVELOPMENT OF LOSMAPIMOD IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| 13.05 11:42 | dpa-AFX: ANALYSE-FLASH: Berenberg belässt Sanofi auf 'Buy' - Ziel 105 Euro |
| 13.05 11:42 | dpa-AFX: Berenberg belässt Sanofi auf 'Buy' - Ziel 105 Euro |
| 13.05 09:57 | MÄRKTE EUROPA/Wenig Bewegung - Preisdaten zur Wochenmitte im Blick |
| 13.05 09:47 | dpa-AFX: *SANOFI AM EUROSTOXX-ENDE -2,9% - KÜNDIGT MILLIARDENINVESTITION IN FRANKREICH AN |
| 13.05 08:04 | Sanofi investiert 1 Mrd Euro in Produktion in Frankreich |
| 13.05 07:56 | dpa-AFX: Regeneron : Dupixent SBLA Accepted For FDA Priority Review For Adolescent Chronic Rhinosinusitis |
| 13.05 07:56 | dpa-AFX: Sanofi To Invest Over EUR 1 Bln Further For Biomanufacturing In France |
| 13.05 07:40 | dpa-AFX: *SANOFI ANNOUNCES INVESTMENT OF MORE THAN EUR 1 BLN TO CREATE NEW BIOPRODUCTION CAPACITY |
| 13.05 07:39 | dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS |
|
|
